Journal article

THE EFFECT OF 3 MONTHS OF RECOMBINANT HUMAN GROWTH-HORMONE (GH) THERAPY ON INSULIN AND GLUCOSE-MEDIATED GLUCOSE DISPOSAL AND INSULIN-SECRETION IN GH-DEFICIENT ADULTS - A MINIMAL MODEL ANALYSIS

DN ONEAL, A KALFAS, PL DUNNING, MJ CHRISTOPHER, SD SAWYER, GM WARD, FP ALFORD

The Journal of Clinical Endocrinology & Metabolism | ENDOCRINE SOC | Published : 1994

Abstract

The effect of 3 months of low dose (120 micrograms/kg.week or 0.24 IU/kg.week) recombinant human GH (rhGH) treatment on glucose tolerance, insulin secretion, and insulin- and glucose-mediated glucose disposal was examined in 10 GH-deficient adults. The frequently sampled iv glucose tolerance test was performed at baseline and after 1 week and 3 months of rhGH therapy and analyzed by the minimal model method of Bergman to provide estimates of the glucose decay rate, first and second phase insulin secretion (phi 1 and phi 2), fractional clearance of insulin, and glucose-mediated and insulin-mediated glucose disposal. Fasting glucose, insulin, C-peptide, nonesterified fatty acids (NEFA), and se..

View full abstract